Gafas de sol Carrera Champion2bZeTetraphase to Pre

Tetraphase to Present at Cambridge Health Institute's Antibacterial Drug Development Conference
- Company to Provide Insights on ˜Targeting
Pathogens Resistant to Current Antibiotics' -
- Applauds WHO for Focus on Antimicrobial Resistance on
World Health Day 2011 -
WATERTOWN, Mass.--(BUSINESS WIRE)--Apr 6, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage life science
company developing a portfolio of potent new antibiotics designed
to be effective against dangerous, drug-resistant bacteria,
including multidrug-resistant (MDR) gram-negative pathogens, today
announced that the Company will present at the Cambridge Health Institute's (CHI) 5th Annual
Antibacterial Drug Development Conference “Resistance is
Futile: The Challenge of Antibacterial Drug Development.”
Joyce Sutcliffe, Ph.D.,lunette ray ban 20112rUB tods online shop-tods for, Tetraphase Senior Vice President, Biology,
will present at 4:00 p.m. on April 12, 2011 on how Tetraphase's
drug candidates target pathogens resistant to currently used
antibiotics.
“At Tetraphase, our current drug candidates are designed
to be effective against dangerous, drug-resistant bacteria,
including multidrug-resistant (MDR) gram-negative pathogens, which
pose a major and growing health threat,” said Dr. Sutcliffe.
“Our lead clinical candidate TP-434, which is being evaluated
in a Phase II study in complicated intra-abdominal infections, is a
broad spectrum intravenous (IV) antibiotic with oral
potential.”
As a company dedicated to addressing the growing health crisis
caused by antibiotic resistance,carrera gafas, Tetraphase applauds the World Health Organization (WHO) for choosing
“antimicrobial resistance and its global spread” as the
theme for World Health Day. On April 7, 2011, WHO will call on
governments and stakeholders to implement policies and practices to
help prevent and counter the emergence of highly resistant
microorganisms.
According to leading infectious disease expert Robert C.
Moellering, Jr., M.D., “We are living in a privileged instant
in time during which medical scientists have found a series of
antibiotics that have given us at best a temporary edge over most
pathogenic bacteria. However, given that bacteria have at least a
two billion-year head start on human existence, it should not be
surprising that their ability to develop resistance to
antimicrobials (honed over their entire period of existence) is
rapidly closing our window of opportunity to maintain the upper
hand. It will require all of our human scientific ingenuity to
maintain the advantage that we have taken for granted for the past
half century." Dr. Moellering is Shields Warren-Mallinckrodt
Professor of Medical Research at Harvard Medical School.
About Tetraphase Pharmaceuticals,carrera gafas de ver, Inc.
Tetraphase Pharmaceuticals is a clinical-stage life science
company with a groundbreaking synthetic chemistry technology
platform that has the power to deliver solutions to the global
health crisis caused by antibiotic resistance. Since the company's
inception in 2006, Tetraphase has developed a robust antibiotic
franchise that offers the potential to dramatically improve the
treatment of both broad and selective spectrum bacterial
infections. To learn more about Tetraphase, please visit www.tphase.com.

Contact: Tetraphase Pharmaceuticals,Gafas de sol Carrera Champion, Inc.
Media Contact:
Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com

Posted: April 2011